Sou Hu Wang·2026-02-27 13:27Core Viewpoint - The launch of Oseltamivir Phosphate Granules by Huize Pharmaceutical on JD Health marks a significant step in providing effective antiviral treatment for influenza, especially for vulnerable populations such as children and the elderly [1][4]. Group 1: Product Overview - Oseltamivir Phosphate Granules are designed for the treatment of influenza, with a broad antiviral activity against both type A and B influenza viruses [1]. - The product is suitable for individuals aged one year and older, offering a convenient oral administration method that reduces the risk of missed doses and resistance [1][2]. - The granule form is particularly child-friendly, making it easier for children to take the medication [1]. Group 2: Efficacy and Safety - The medication has shown significant efficacy in benefiting influenza patients, with sufficient evidence supporting its use for COVID-19 and hand-foot-mouth disease patients as well [2]. - It is deemed safe for use in infants over 14 days old, pregnant women, and the elderly [3]. Group 3: Quality Assurance and Company Background - The product has passed the national consistency evaluation and is classified under the national medical insurance category B [4]. - Huize Pharmaceutical, established in 2014, is recognized as one of the top 20 CRO companies in China and has received various accolades, including being a national high-tech enterprise [4]. Group 4: Strategic Collaboration - The online launch is a starting point for deeper collaboration between Huize Pharmaceutical and JD Health, leveraging JD Health's marketing resources and supply chain to enhance patient access to the medication [4]. - Future cooperation will focus on the entire cycle of influenza prevention and treatment, including drug accessibility, patient education, and influenza warning systems [4].